ESCO1 stabilizes NUFIP2 through acetylation–ubiquitination crosstalk to promote pancreatic cancer progression
- 1Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University , , ,
- 2Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University , , ,
Abstract
Background: Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, and its molecular pathogenesis remains incompletely understood, with effective therapeutic options still limited. Establishment of sister chromatid cohesion N-acetyltransferase 1 (ESCO1) has been implicated in the development and progression of several malignancies; however, its biological role and underlying mechanisms in pancreatic cancer remain largely unknown. This study aimed to elucidate the clinical significance and molecular mechanisms of the ESCO1/NUFIP2 axis in pancreatic cancer.
Methods: TCGA, CPTAC, and other publicly available datasets were used to evaluate the expression patterns, diagnostic value, and prognostic significance of ESCO1 and NUFIP2 in pancreatic cancer. In vitro and in vivo experiments were subsequently performed to characterize the biological functions of the ESCO1/NUFIP2 axis and elucidate its underlying molecular mechanisms.
Results: ESCO1 and NUFIP2 were significantly upregulated in pancreatic cancer and were associated with poor prognosis. Functional assays demonstrated that the ESCO1/NUFIP2 axis promoted pancreatic cancer cell proliferation and migration, enhanced tumor growth in vivo , and suppressed apoptosis. Mechanistically, ESCO1 promoted NUFIP2 acetylation and limited its K48-linked ubiquitination and subsequent degradation, thereby maintaining NUFIP2 protein stability. Stabilized NUFIP2 preserved mitochondrial function and suppressed mitochondrial apoptosis, whereas NUFIP2 overexpression or trichostatin A (TSA) treatment partially reversed the effects of ESCO1 depletion. Moreover, the ESCO1/NUFIP2 axis was associated with immune cell infiltration, and depletion of either ESCO1 or NUFIP2 enhanced dendritic cell (DC)-mediated cytotoxic T lymphocyte (CTL) antitumor responses.
Conclusion: ESCO1 stabilizes NUFIP2 through acetylation-dependent regulation, thereby preserving mitochondrial function, suppressing mitochondrial apoptosis, and promoting pancreatic cancer progression. The ESCO1/NUFIP2 axis may also contribute to the regulation of antitumor immunity, highlighting its potential as a biomarker and therapeutic target in pancreatic cancer.
Related
- SPP1-CD44-Mediated Crosstalk Between Endothelial and Macrophage Subpopulations Promotes Pancreatic Ductal Adenocarcinoma Progression Through S100A6 Upregulation
- LncRNA HITT stabilizes SIRT6 to restrain H3/H4 acetylation and suppress colorectal cancer growth
- CST1 stabilizes GPX4 to suppress ferroptosis and promote bladder cancer progression
- Extravascular coagulation stabilizes pro-fibrotic stromal states via tumor-intrinsic PAR1 signaling in pancreatic ductal adenocarcinoma
- Acetylation of JUP at Lys326 promotes gastric cancer progression by enhancing TCF4 transcriptional activity
BibTeX
@article{chen2026esco1,
title = {{ESCO1 stabilizes NUFIP2 through acetylation–ubiquitination crosstalk to promote pancreatic cancer progression}},
author = {Letian Chen and Zihan Yan and Yuting Rao and Xiaowei Fu and Keyi Fang and Zijian Zhou and Xiaogang Peng and Yeqing Zou},
journal = {Frontiers in immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1929713},
url = {https://europepmc.org/article/PMC/PMC13672342},
note = {CC BY},
}
RIS
TY - JOUR
TI - ESCO1 stabilizes NUFIP2 through acetylation–ubiquitination crosstalk to promote pancreatic cancer progression
AU - Letian Chen
AU - Zihan Yan
AU - Yuting Rao
AU - Xiaowei Fu
AU - Keyi Fang
AU - Zijian Zhou
AU - Xiaogang Peng
AU - Yeqing Zou
PY - 2026
DA - 2026/10/02
JO - Frontiers in immunology
DO - 10.3389/fimmu.2026.1929713
UR - https://europepmc.org/article/PMC/PMC13672342
AB - Background: Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, and its molecular pathogenesis remains incompletely understood, with effective therapeutic options still limited. Establishment of sister chromatid cohesion N-acetyltransferase 1 (ESCO1) has been implicated in the development and progression of several malignancies; however, its biological role and underlying mechanisms in pancreatic cancer remain largely unknown. This study aimed to elucidate the clinical significance and molecular mechanisms of the ESCO1/NUFIP2 axis in pancreatic cancer. Methods: TCGA, CPTAC, and other publicly available datasets were used to evaluate the expression patterns, diagnostic value, and prognostic significance of ESCO1 and NUFIP2 in pancreatic cancer. In vitro and in vivo experiments were subsequently performed to characterize the biological functions of the ESCO1/NUFIP2 axis and elucidate its underlying molecular mechanisms. Results: ESCO1 and NUFIP2 were significantly upregulated in pancreatic cancer and were associated with poor prognosis. Functional assays demonstrated that the ESCO1/NUFIP2 axis promoted pancreatic cancer cell proliferation and migration, enhanced tumor growth in vivo , and suppressed apoptosis. Mechanistically, ESCO1 promoted NUFIP2 acetylation and limited its K48-linked ubiquitination and subsequent degradation, thereby maintaining NUFIP2 protein stability. Stabilized NUFIP2 preserved mitochondrial function and suppressed mitochondrial apoptosis, whereas NUFIP2 overexpression or trichostatin A (TSA) treatment partially reversed the effects of ESCO1 depletion. Moreover, the ESCO1/NUFIP2 axis was associated with immune cell infiltration, and depletion of either ESCO1 or NUFIP2 enhanced dendritic cell (DC)-mediated cytotoxic T lymphocyte (CTL) antitumor responses. Conclusion: ESCO1 stabilizes NUFIP2 through acetylation-dependent regulation, thereby preserving mitochondrial function, suppressing mitochondrial apoptosis, and promoting pancreatic cancer progression. The ESCO1/NUFIP2 axis may also contribute to the regulation of antitumor immunity, highlighting its potential as a biomarker and therapeutic target in pancreatic cancer.
SN - 1664-3224
ER -